Berkeley, CA and Vancouver, BC – March 7, 2017 – BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSXV: BCT) (OTCQB: BCTXF) today announced that it has filed an international patent application under the Patent Cooperation Treaty (PCT) to further expand its intellectual property portfolio underlying the Company’s current and anticipated pipeline of whole-cell cancer vaccines, …
Berkeley, CA and Vancouver, BC – February 27, 2017 – BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSXV: BCT) (OTCQB: BCTXF) announced today that its President and CEO, Dr. William Williams has entered into a non-brokered private placement (the “Offering”) of 5,416,667 units of the Company (the “Units”) at a price of C$0.24 per Unit …
Berkeley, CA and Vancouver, BC – February 6, 2017 – BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSXV: BCT) (OTCQB: BCTXF), a clinical-stage company dedicated to the development of immuno-oncology treatments, today announced that the Company has submitted a Chemistry, Manufacturing, and Controls (CMC) amendment which includes the details of extensive testing performed on BriaVax™, …
Berkeley, CA and Vancouver, BC – January 5, 2017 – BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSXV: BCT) (OTCQB: BCTXF), a clinical-stage immuno-oncology company dedicated to the development of novel immuno-oncology therapeutics, today announced that Jason Napodano, senior equity analyst at BioNap Consulting, Inc., included BriaCell in the list of key players in immuno-oncology. …
Dr. Lacher’s interview with GenomeWeb – Dec 2016
Berkeley, CA and Vancouver, BC – December 5, 2016 – BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSXV: BCT) (OTCQB: BCTXF), a clinical-stage company dedicated to the development of immuno-oncology treatments, today announced that the Company will present the latest development update for BriaVax™, the Company’s proprietary vaccine for advanced breast cancer, at the 39th …
Berkeley, CA and Vancouver, BC – November 29, 2016 – BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSXV: BCT) (OTCQB: BCTXF), a clinical-stage immuno-oncology company dedicated to the development of immuno-oncology treatments, is pleased to announce that it has filed a patent application with the U.S. Patent and Trademark Office (USPTO) as basis for potential …
Berkeley, CA and Vancouver, BC – November 10, 2016 – BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSXV: BCT) (OTCQB: BCTXF), a clinical-stage immuno-oncology company dedicated to the development of immuno-oncology treatments that can enhance the lives of cancer patients, today provided a comprehensive clinical development update for BriaVax™, its proprietary vaccine for advanced breast …
Berkeley, CA and Vancouver, BC – October 26, 2016 – BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSXV: BCT) (OTCQB: BCTXF), a clinical-stage immuno-oncology company dedicated to the development of immuno-oncology treatments that can enhance the lives of cancer patients, is pleased to announce the appointment of Dr. William Williams, as its President, CEO and …
Berkeley, CA and Vancouver, BC–(Marketwired – September 27, 2016) – BioNap Consulting, Inc.’s Senior Equity Analyst, Jason Napodano, CFA, issued an update outlining the meaningful progress of BriaCell Therapeutics Corp. (TSX VENTURE: BCT) (OTCQB: BCTXF) or BriaCell towards initiation of Phase I/IIa clinical testing of BriaVax™, BriaCell’s proprietary allogeneic whole tumor cell vaccine, in late-stage …